ArticleMolecular therapy oncolytics2017

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Sam Illingworth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.